Clinical Study on Treatment of Allergic Conjunctivitis with Chuanjiao Fang 1

Clinical Study on Prevention and Treatment of Allergic Conjunctivitis with Traditional Chinese Medicine

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2022000061

Enrollment

Unknown

Registered

2022-07-13

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

Control group:Chuan Jiaofang 1 Placebo + Cetirizine Tablets+Sodium Hyaluronate Eye Drops

Treatment group:Chuanjiao Fang 1 + Cetirizine Tablets Placebo+Sodium Hyaluronate Eye Drops

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria of allergic conjunctivitis; Sign the informed consent form.

Exclusion criteria

Exclusion criteria: Have other serious eye diseases in addition to allergic conjunctivitis; Have undergone ophthalmic surgery in the previous 6 months; Allergic to the components of the drug; The keratoscope was worn during the study; Concurrent use of drugs that interfere with the evaluation of drug efficacy ; Pregnant or breastfeeding women; Combined with serious primary diseases of cardiovascular,cerebrovascular, liver and kidney,hematopoietic system and mental patients.

Design outcomes

Primary

Measure	Time frame
Ocular symptoms;Ocular signs;	—

Secondary

Measure	Time frame
Nasal symptoms;	—

Countries

China

Contacts

Public ContactSong Jiantao

Jangts@163.com18600410188

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026